Tirzepatide Once Weekly for the Treatment of Obesity – American College of Cardiology
Dharam J. Kumbhani, MD, SM, FACC; Neil Keshvani, MD
Related Articles
Ticking Time Bomb: Embolic Risks and Complex Management of an Exceptionally Large Papillary Fibroelastoma
Papillary fibroelastomas (PFEs) are now believed to be the most common benign primary cardiac tumors, with increasing incidence due to improved detection by echocardiography.1 They…
ACC Announces 2025 Distinguished Award Recipients – American College of Cardiology
The ACC is pleased to announce the recipients of its 2025 Distinguished Awards. This year’s honorees represent an inspiring group of individuals who hav e…
The primary reason Boston Scientific’s TAVR valve fell short in clinical trial
Michael Reardon, MD, co-principal investigator of the ACURATE IDE trial, discussed updated data on what may have impacted that study’s findings.
Stryker to Acquire Inari Medical – Endovascular Today
January 6, 2025—Stryker announced a definitive agreement to acquire Inari Medical, Inc. for approximately $4.9 billion. Inari was founded in 201
Study Links Osteoporosis Injections and Increased MACE in Dialysis Patients
In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates.
2025 Ralph L. Sacco Scholarships in Brain Health
Find the answers to your proposal submission questions, plus links to the best resources for building a strong research application. Proposal deadline: Thurs., Jan. 30,…
Synchron on LinkedIn: Brain implant that’s ahead of Elon Musk in the race to read minds
The Times speaks with our CEO Thomas Oxley: Read the article by Rhys Blakely: https://lnkd.in/eSX-h4Qv
ACC Announces 2025 Distinguished Award Recipients – American College of Cardiology
The ACC is pleased to announce the recipients of its 2025 Distinguished Awards. This year’s honorees represent an inspiring group of individuals who hav e…
Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments
The device was not included as a potential treatment despite sham-controlled evidence showing it reduces patient symptoms.